Compounded tirzepatide

Does insurance cover compounded tirzepatide?

Quick answer

Not the compounded vial. A plan that covers tirzepatide covers an approved product: Zepbound for weight management or Mounjaro for type 2 diabetes, depending on your indication and formulary. Compounded tirzepatide is a cash market, and it says so: 43 of the 383 sellers on this index advertise “no insurance required” as a reason to buy.

If your plan declines Zepbound, the self-pay vial is the number to beat: $299 a month at the starting strength and $449 from 7.5 mg up.

What the sellers themselves say

This is not a claim about your plan. It is a count of what 68 sellers wrote on their own pages, read on a recorded date. Three examples, quoted exactly:

  • “We do not accept insurance. Luma Health Co. operates on a direct-to-patient model.”
  • “At this time, we do not work with medical insurance.” — Telehealth Weight Solutions
  • “No insurance needed” — printed beside the price, on seller after seller

That last one is the point. A cash price is not something these sellers apologize for; it is the pitch. Skipping insurance is how a telehealth seller can put a number on a landing page at all — and it is why this index can compute one.

One seller runs both tracks, which settles it

Measured publishes two lines of business side by side. Its compounded plan is all-in cash and its own page says “No insurance required”. Its brand-name plan — the same company, the same checkout — reads “Medication covered by insurance or cash pay”.

Insurance attaches to the approved product. It does not follow the molecule into a compounded vial. You can see the split inside a single seller’s pricing.

The one insurance-first practice we have checked makes the same point from the other side: it is a primary-care group where medication runs through your plan, and it publishes no medication price at all — because there isn’t one to publish. What you pay depends on your formulary, not on the seller.

If you do have coverage, price Zepbound or Mounjaro

This is the useful version of the answer. If your plan covers tirzepatide for your indication, the thing to price is Zepbound or Mounjaro, not a compounded vial — and your copay may well beat every number on this site.

If it does not, the comparison that matters is against Eli Lilly’s own self-pay vial rather than against a copay you cannot get. Lilly sells Zepbound direct at $299 a month at 2.5 mg and $449 from 7.5 mg, against a compounded median of $269. The dose-by-dose crossover is worked out on compounded vs Zepbound.

HSA and FSA are a different question, and often yes

20 sellers in this index advertise that they are HSA or FSA eligible. That is not insurance — nobody is adjudicating a claim — but it does mean many readers can pay with pre-tax dollars, which is a real discount on a cash price.

Eligibility depends on your own plan administrator and on having a prescription, so check with them rather than with the seller. What the seller can tell you is whether it will accept the card, and what else it will charge you once it does.

Nothing here is advice about your coverage, and nothing is a recommendation to start, stop or switch a medication. See the medical disclaimer.